# Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years

> **NCT05762523** · PHASE1 · COMPLETED · sponsor: **Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"** · enrollment: 60 (actual)

## Conditions studied

- Smallpox
- Monkeypox
- Cowpox
- Vaccinia Virus Infection

## Interventions

- **BIOLOGICAL:** VAC∆6 vaccine - оnce at a dose of 10⁶ PFU
- **BIOLOGICAL:** VAC∆6 vaccine - once at a dose of 10⁷ PFU
- **BIOLOGICAL:** VAC∆6 vaccine - twice at a dose of 10⁶ PFU
- **BIOLOGICAL:** Live smallpox vaccine (Smallpox vaccine) + The OspaVir® inactivated smallpox vaccine

## Key facts

- **NCT ID:** NCT05762523
- **Lead sponsor:** Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-18
- **Primary completion:** 2019-07-22
- **Final completion:** 2020-01-27
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2023-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05762523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05762523, "Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05762523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*